Abstract
Twenty-three (23) derivatives of coumarin (5-27) were synthesized and screened for their in vitro β- glucuronidase (E. coli) inhibitory activities. Only three compounds, 7,8-dihydroxy-4-methyl-2H-chromen-2-one (9) (IC50 = 52.39 ± 1.85 µM), 3-chloro-6-hexyl-7-hydroxy-4-methyl-2H-chromen-2-one (18) (IC50 = 60.50 ± 0.87 µM), and 3,6- dichloro-7-hydroxy-4-methyl-2H-chromen-2-one (15) (IC50 = 380.26 ± 0.92 µM) displayed activities against β- glucuronidase as compared to standard D-saccharic acid 1,4-lactone (IC50 = 45.75 ± 2.16 µM). The results indicated that the activity of the synthetic coumarins depends upon the substituents present on the coumarin skeleton.
Keywords: β-glucuronidase, coumarin, Pechmann reaction, enzyme inhibition, β-glucuronidase related disorders, acid catalysis.
Graphical Abstract
Medicinal Chemistry
Title:β-Glucuronidase Inhibitory Studies on Coumarin Derivatives
Volume: 10 Issue: 8
Author(s): Khalid Mohammed Khan, Muhammad Imran Fakhri, Nimra Naveed Shaikh, Syed Muhammad Saad, Shafqat Hussain, Shahnaz Perveen and Muhammad Iqbal Choudhary
Affiliation:
Keywords: β-glucuronidase, coumarin, Pechmann reaction, enzyme inhibition, β-glucuronidase related disorders, acid catalysis.
Abstract: Twenty-three (23) derivatives of coumarin (5-27) were synthesized and screened for their in vitro β- glucuronidase (E. coli) inhibitory activities. Only three compounds, 7,8-dihydroxy-4-methyl-2H-chromen-2-one (9) (IC50 = 52.39 ± 1.85 µM), 3-chloro-6-hexyl-7-hydroxy-4-methyl-2H-chromen-2-one (18) (IC50 = 60.50 ± 0.87 µM), and 3,6- dichloro-7-hydroxy-4-methyl-2H-chromen-2-one (15) (IC50 = 380.26 ± 0.92 µM) displayed activities against β- glucuronidase as compared to standard D-saccharic acid 1,4-lactone (IC50 = 45.75 ± 2.16 µM). The results indicated that the activity of the synthetic coumarins depends upon the substituents present on the coumarin skeleton.
Export Options
About this article
Cite this article as:
Khan Mohammed Khalid, Fakhri Imran Muhammad, Shaikh Naveed Nimra, Saad Muhammad Syed, Hussain Shafqat, Perveen Shahnaz and Choudhary Iqbal Muhammad, β-Glucuronidase Inhibitory Studies on Coumarin Derivatives, Medicinal Chemistry 2014; 10 (8) . https://dx.doi.org/10.2174/1573406410666140311093352
DOI https://dx.doi.org/10.2174/1573406410666140311093352 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets HuR as Therapeutic Target in Cancer: What the Future Holds
Current Medicinal Chemistry HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Honey, Health and Longevity
Current Aging Science Intranasal Drug Delivery for Brain Targeting
Current Drug Delivery Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology
Recent Patents on DNA & Gene Sequences Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Histone Deacetylase Inhibitors and Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Current Cancer Drug Targets Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets Raman Molecular Imaging of Cells and Tissues: Towards Functional Diagnostic Imaging Without Labeling
Current Pharmaceutical Biotechnology Interaction Between Retinoids and Eicosanoids: Their Relevance to Cancer Chemoprevention
Current Nutrition & Food Science Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science